文献速递免疫规划妇幼与学校卫生

一项III期、多中心、随机、双盲、阳性对照研究:评估V114与PCV13在健康婴儿中的安全性、耐受性和免疫原性(PNEU-PED-EU-1)

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
PubMed 文献 · Vaccine · 2023-04-25

该III期多中心随机双盲阳性对照研究在1184名42-90日龄健康婴儿中比较V114与PCV13按2+1程序接种的安全性及免疫原性。V114对13个共有血清型的免疫应答非劣效于PCV13,对额外血清型22F和33F的应答优于PCV13,安全性特征相当,同时接种DTPa-HBV-IPV/Hib和轮状病毒RV1疫苗的抗体应答亦达非劣效标准。

要点

  • V114对13个共有血清型的免疫应答非劣效于PCV13。
  • V114对额外血清型22F和33F的免疫应答优于PCV13。
  • 两组征集性不良事件和严重不良事件比例相当。

核心结论

  • 按2+1程序接种后,V114对13个共有血清型诱导非劣效免疫应答,对两个额外血清型诱导优于PCV13的应答,安全性特征相当。
  • 结果支持V114在婴儿中的常规使用。

研究设计与样本

  • III期、多中心、随机、双盲、阳性对照研究。
  • 1184名42-90日龄健康婴儿按1:1随机分配至V114组(n=591)或PCV13组(n=593)。
  • V114和PCV13按2+1程序在2、4和11-15月龄接种。
  • 每次接种后第1-14天收集不良事件。
  • 在基础免疫系列后30天、幼儿剂次接种前即刻和幼儿剂次接种后30天检测血清型特异性抗肺炎球菌免疫球蛋白G(IgG)。

主要发现

  • V114组和PCV13组中发生征集性不良事件和严重不良事件的参与者比例相当。
  • V114对所有13个共有血清型均达到预设非劣效标准,依据为血清型特异性IgG浓度≥0.35 μg/mL的参与者比例差异(应答率;双侧95%置信区间[CI]下限>-10.0)和IgG几何平均浓度(GMC)比值(双侧95%CI下限>0.5)。
  • V114对血清型22F和33F达到预设优效标准(应答率双侧95%CI下限>10.0,GMC比值双侧95%CI下限>2.0)。
  • 对DTPa-HBV-IPV/Hib和RV1疫苗的抗体应答达到预设非劣效标准,依据为DTPa-HBV-IPV/Hib抗原特异性应答率和抗轮状病毒IgA几何平均滴度。

关键数值与推荐

  • V114对13个共有血清型的非劣效标准:应答率差异双侧95%CI下限>-10.0,IgG GMC比值双侧95%CI下限>0.5。
  • V114对血清型22F和33F的优效标准:应答率双侧95%CI下限>10.0,GMC比值双侧95%CI下限>2.0。

临床怎么用

  • 作者认为结果支持V114在婴儿中的常规使用。
  • 原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: V114 (15-valent pneumococcal conjugate vaccine [PCV]) contains all serotypes in 13-valent PCV (PCV13) and additional serotypes 22F and 33F. This study evaluated safety and immunogenicity of V114 compared with PCV13 in healthy infants, and concomitant administration with DTPa-HBV-IPV/Hib and rotavirus RV1 vaccines. METHODS: V114 and PCV13 were administered in a 2+1 schedule at 2, 4, and 11-15 months of age. Adverse events (AEs) were collected on Days 1-14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-primary series (PPS), immediately prior to a toddler dose, and 30 days post-toddler dose (PTD). Primary objectives included non-inferiority of V114 to PCV13 for 13 shared serotypes and superiority of V114 to PCV13 for the two additional serotypes. RESULTS: 1184 healthy infants 42-90 days of age were randomized 1:1 to V114 (n = 591) or PCV13 (n = 593). Proportions of participants with solicited AEs and serious AEs were comparable between vaccination groups. V114 met pre-specified non-inferiority criteria for all 13 shared serotypes, based on the difference in proportions of participants with serotype-specific IgG concentrations ≥0.35 μg/mL (response rate; lower bound of two-sided 95% confidence interval [CI] >-10.0) and IgG geometric mean concentration (GMC) ratios (lower bound of two-sided 95% CI >0.5), and pre-specified superiority criteria for serotypes 22F and 33F (lower bound of two-sided 95% CI >10.0 for response rates and >2.0 for GMC ratios). Antibody responses to DTPa-HBV-IPV/Hib and RV1 vaccines met pre-specified non-inferiority criteria, based on antigen-specific response rates to DTPa-HBV-IPV/Hib and anti-rotavirus IgA geometric mean titers. CONCLUSIONS: After a 2+1 schedule, V114 elicited non-inferior immune responses to 13 shared serotypes and superior responses to the two additional serotypes compared with PCV13, with comparable safety profile. These results support the routine use of V114 in infants. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04031846; EudraCT: 2018-003787-31.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Martinon-Torres F, Wysocki J, Szenborn L, et al. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Vaccine. 2023. PMID: 37105892. doi:10.1016/j.vaccine.2023.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。